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Docetaxel Consolidation Therapy Following Cisplatin,
Vinorelbine, and Concurrent Thoracic Radiotherapy in
Patients with Unresectable Stage III Non-small
Cell Lung Cancer
Ikuo Sekine,* Hiroshi Nokihara,* Minako Sumi,† Nagahiro Saijo,‡
Yutaka Nishiwaki,§ Satoshi Ishikura, Kiyoshi Mori,¶ Iwao Tsukiyama,#
and Tomohide Tamura*
Background: To evaluate the feasibility and efficacy of docetaxel
consolidation therapy after concurrent chemoradiotherapy for unre-
sectable stage III non–small cell lung cancer (NSCLC).
Patients and Methods: The eligibility criteria included unresect-
able stage III NSCLC, no previous treatment, age between 20 and 74
years, and performance status 0 or 1. Treatment consisted of cispla-
tin (80 mg/m2 on days 1, 29, and 57), vinorelbine (20 mg/m2 on days
1, 8, 29, 36, 57, and 64), and thoracic radiotherapy (TRT) (60 Gy/30
fractions over 6 weeks starting on day 2), followed by consolidation
docetaxel (60 mg/m2 every 3 to 4 weeks for three cycles).
Results: Of 97 patients who were enrolled in this study between
2001 and 2003, 93 (76 males and 17 females with a median age of
60) could be evaluated. Chemoradiotherapy was well tolerated; three
cycles of chemotherapy and 60 Gy of TRT were administered in 80
(86%) and 87 (94%) patients, respectively. Grade 3 or 4 neutropenia,
esophagitis, and pneumonitis developed in 62, 11, and 3 patients,
respectively. Docetaxel consolidation was administered in 59 (63%)
patients, but three cycles were completed in only 34 (37%) patients.
The most common reason for discontinuation was pneumonitis,
which developed in 14 (24%) of the 59 patients. During consolida-
tion therapy, grade 3 or 4 neutropenia, esophagitis, and pneumonitis
developed in 51, 2, and 4 patients, respectively. A total of four
patients died of pneumonitis. We calculated a V20 (the percent
volume of the normal lung receiving 20 Gy or more) on a dose–
volume histogram in 25 patients. Of these, five patients developed
grade 3 or more severe radiation pneumonitis. A median V20 for
these five patients was 35% (range, 26–40%), whereas the median
V20 for the remaining 20 patients was 30% (range, 17–35%) (p 
0.035 by a Mann–Whitney test). The response rate was 81.7% (95%
confidence interval [CI], 72.7–88.0%), with 5 complete and 71
partial responses. The median progression-free survival was 12.8
(CI, 10.2–15.4) months, and median survival was 30.4 (CI, 24.5–
36.3) months. The 1-, 2-, and 3-year survival rates were 80.7, 60.2,
and 42.6%, respectively.
Conclusion: This regimen produced promising overall survival in
patients with stage III NSCLC, but the vast majority of patients could
not continue with the docetaxel consolidation because of toxicity.
Key Words: Non-small cell lung cancer, Chemoradiotherapy, Con-
solidation, Docetaxel.
(J Thorac Oncol. 2006;1: 810–815)
Locally advanced unresectable non–small cell lung cancer(NSCLC), stage IIIA with bulky N2 and stage IIIB disease
without pleural effusion, is characterized by large primary
lesions and/or involvement of the mediastinal or supraclavic-
ular lymph nodes and occult systemic micrometastases. A
combination of thoracic radiotherapy and chemotherapy is
the standard medical treatment for this disease, but the opti-
mal combination has not been established.1 Although the
available data are insufficient to accurately define the size of
a potential benefit,2 concurrent chemoradiotherapy using a
platinum doublet has been shown to be superior to the sequential
approach in phase III trials of this disease.3–5 However, third-
generation cytotoxic agents, which have provided better patient
survival with extrathoracic spread than the old-generation
agents, must be reduced when administered concurrently with
thoracic radiotherapy.6 Thus, it has been hypothesized that the
addition of systemic dose chemotherapy with a new cytotoxic
agent to concurrent chemoradiotherapy, either as induction or
as consolidation chemotherapy, might further improve patient
survival.1
The consolidation chemotherapy with docetaxel was
based on the observation that this drug was highly active in
the primary treatment of metastatic NSCLC, producing a
response rate (RR) as high as 20% after platinum-based
chemotherapy failed.7–9 Highly encouraging results of a me-
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dian survival time (MST) of more than 2 years and a 3-year
survival rate of nearly 40% were obtained in a phase II trial
of docetaxel consolidation after chemoradiotherapy with cis-
platin and etoposide in patients with stage IIIB NSCLC
(SWOG study S9504).10
We have developed a combination chemotherapy sched-
ule with cisplatin and vinorelbine concurrently administered
with thoracic radiotherapy at a total dose of 60 Gy in 30 fractions
in patients with unresectable stage III NSCLC. The results of a
phase I study in 18 patients were very promising, with a RR of
83%, a MST of 30 months, and a 3-year survival rate of 50%.6
Thus, addition of docetaxel consolidation to this regimen is a
particularly interesting therapeutic strategy. The objectives of
the current study were to evaluate the feasibility of docetaxel
consolidation therapy after concurrent chemoradiotherapy with
cisplatin and vinorelbine and to evaluate the efficacy and safety
of the whole treatment regimen including both the chemoradio-
therapy and consolidation therapy in patients with unresectable
stage IIIA and IIIB NSCLC.
PATIENTS AND METHODS
Patient Selection
The eligibility criteria were histologically or cytologi-
cally proven NSCLC; unresectable stage IIIA or IIIB disease;
no previous treatment; measurable disease; tumor within an
estimated irradiation field no larger than half the hemithorax;
age between 20 and 74 years; Eastern Cooperative Oncology
Group performance status (PS) of 0 or 1; adequate bone
marrow function (12.0  109/liter  white blood cell [WBC]
count 4.0  109/liter, neutrophil count 2.0  109/liter,
hemoglobin10.0 g/dl, and platelet count100 109/liter),
liver function (total bilirubin1.5 mg/dl and transaminase no
more than twice the upper limit of the normal value), and
renal function (serum creatinine 1.5 mg/dl and creatinine
clearance 60 ml per minute); and a PaO2 of 70 torr or more
under room air conditions. Patients were excluded if they had
malignant pleural or pericardial effusion, active double can-
cer, a concomitant serious illness such as uncontrolled angina
pectoris, myocardial infarction in the previous 3 months,
heart failure, uncontrolled diabetes mellitus, uncontrolled
hypertension, interstitial pneumonia or lung fibrosis identified
by a chest x-ray, chronic obstructive lung disease, infection or
other diseases contraindicating chemotherapy or radiother-
apy, pregnancy, or if they were breast feeding. All patients
gave their written informed consent.
Pretreatment Evaluation
The pretreatment assessment included a complete blood
cell count and differential count, routine chemistry determi-
nations, creatinine clearance, blood gas analysis, electrocar-
diogram, lung function testing, chest x-rays, chest computed
tomographic (CT) scan, brain CT scan or magnetic resonance
imaging, abdominal CT scan or ultrasonography, and radio-
nuclide bone scan.
Treatment Schedule
Treatment consisted of a chemoradiotherapy phase with
three cycles of cisplatin and vinorelbine followed by a con-
solidation phase with three cycles of docetaxel (Figure 1).
Cisplatin 80 mg/m2 was administered on days 1, 29, and 57
by intravenous infusion for 60 minutes with 2500 to 3000 ml
of fluid for hydration. Vinorelbine diluted in 50 ml of normal
saline was administered intravenously on days 1, 8, 29, 36,
57, and 64. All patients received prophylactic antiemetic
therapy consisting of a 5HT3-antagonist and a steroid.
Radiation therapy was delivered with megavoltage
equipment (6 MV) using anterior/posterior opposed fields
up to 40 Gy in 20 fractions including the primary tumor, the
metastatic lymph nodes, and the regional nodes. A booster
dose of 20 Gy in 10 fractions was given to the primary tumor
and the metastatic lymph nodes for a total dose of 60 Gy
using bilateral oblique fields. A CT scan–based treatment
planning was used in all patients. The clinical target volume
(CTV) for the primary tumor was defined as the gross tumor
volume (GTV) plus 1 cm taking account of subclinical
extension. CTV and GTV for the metastatic nodes (1 cm in
shortest dimension) were the same. Regional nodes, exclud-
ing the contralateral hilar and supraclavicular nodes, were
included in the CTV, but the lower mediastinal nodes were
included only if the primary tumor was located in the lower
lobe of the lung. The planning target volumes for the primary
tumor, the metastatic lymph nodes, and regional nodes were
determined as CTVs plus 0.5- to 1.0-cm margins laterally and
1.0- to 2.0-cm margins craniocaudally, taking account of
setup variations and internal organ motion. Lung heteroge-
neity corrections were not used.
The criteria for starting consolidation chemotherapy
were completion of three cycles of cisplatin and vinorelbine
and a full dose of thoracic radiotherapy, the absence of progres-
sive disease, adequate general condition within 6 weeks of the
start of the third cycle of cisplatin and vinorelbine (PS 0 or 1,
WBC count3.0 109/liter, neutrophil count1.5 109/liter,
hemoglobin9.0 g/dl and platelet count100 109/liter, total
bilirubin 1.5 mg/dl and transaminase no more than twice the
upper limit of the normal value, and a PaO2 of 70 torr or more
at room air). Docetaxel (60 mg/m2) was administered intrave-
nously for 1 hour every 3 to 4 weeks for three cycles.
Toxicity Assessment and Treatment
Modification
Complete blood cell counts and differential counts,
routine chemistry determinations, and a chest x-ray were
performed once a week during the course of treatment. Acute
toxicity was graded according to the NCI Common Toxicity
Criteria, and late toxicity associated with thoracic radiother-
FIGURE 1. Treatment schema. CDDP, cisplatin; DTX, do-
cetaxel; TRT, thoracic radiotherapy; VNR, vinorelbine.
Journal of Thoracic Oncology • Volume 1, Number 8, October 2006 Docetaxel Consolidation after Chemoradiotherapy
Copyright © 2006 by the International Association for the Study of Lung Cancer 811
apy was graded according to the Radiation Therapy Oncology
Group/European Organization for Research and Treatment of
Cancer late radiation morbidity scoring scheme. Vinorelbine
administration on day 8 was omitted if any of the following
were noted: WBC count 3.0  109/liter, neutrophil count
1.5  109/liter, platelet count 100  109/liter, elevated
hepatic transaminase level or total serum bilirubin of at least
grade 2, fever 38°C, or PS 2. Subsequent cycles of
cisplatin and vinorelbine chemotherapy were delayed if any
of the following toxicities were noted on day 1: WBC count
3.0  109/liter, neutrophil count 1.5  109/liter, platelet
count 100  109/liter, serum creatinine level 1.6 mg/dl,
elevated hepatic transaminase level or total serum bilirubin of
at least grade 2, fever38°C, or PS2. The dose of cisplatin
was reduced by 25% in all subsequent cycles if the serum
creatinine level rose to 2.0 mg/dl or higher. The dose of
vinorelbine or docetaxel was reduced by 25% in all subse-
quent cycles if any of the following toxicities were noted:
WBC count 1.0  109/liter, platelet count 10  109/liter,
or grade 3 or 4 infection or liver dysfunction. Thoracic
radiotherapy was suspended if any of the following were
noted: fever 38°C, grade 3 esophagitis, PS of 3, or PaO2
70 torr. Thoracic radiotherapy was terminated if any of the
following were noted: grade 4 esophagitis, grade 3 or 4
pneumonitis, PS of 4, or duration of radiotherapy of over 60
days. The use of granulocyte colony-stimulating factor during
radiotherapy was not permitted unless radiotherapy was on
hold. The criteria for termination of docetaxel consolidation
were not defined in the protocol.
Response Evaluation
Objective tumor response was evaluated according to
the Response Evaluation Criteria in Solid Tumor.11 Local
recurrence was defined as tumor progression in the primary
site and in the hilar, mediastinal, and supraclavicular lymph
nodes after a partial or complete response; regional recur-
rence as the development of malignant pleural and pericardial
effusions; and distant recurrence as the appearance of a
distant metastasis.
Study Design, Data Management,
and Statistical Considerations
This study was conducted at three institutions: the
National Cancer Center Hospital, National Cancer Center
Hospital East, and Tochigi Cancer Center. The protocol and
consent form were approved by the institutional review board
of each institution. Registration was conducted at the regis-
tration center. Data management, periodic monitoring, and
the final analysis were performed by the study coordinator.
The primary objective of the current study was to
evaluate the feasibility of docetaxel consolidation therapy.
The secondary endpoints were toxicity observed during che-
moradiotherapy and consolidation therapy, the best response,
and overall survival in all patients eligible to participate in
this study. Because no standard method to evaluate consoli-
dation chemotherapy after chemoradiotherapy has been es-
tablished, we arbitrarily defined the primary endpoint of this
study as a ratio (R) of the number of patients receiving
docetaxel without grade 4 nonhematological toxicity or treat-
ment-related death to the total number of patients receiving
docetaxel. The sample size was initially estimated to be 34
patients with a power of 0.80 at a significance level of 0.05,
under the assumption that a R of 0.95 would indicate poten-
tial usefulness, whereas a R of 0.8 would be the lower limit
of interest, and that 85% of patients would move into the
consolidation phase. An analysis of the first 13 patients,
however, showed that only 8 (61%) patients advanced into
the consolidation phase. The reasons for not receiving do-
cetaxel were disease progression in one, delay in completion
of chemoradiotherapy in two, grade 3 esophagitis in one, and
death due to hemoptysis in one patient. Considering that the
SWOG trial S9504 included 83 patients, we decided to revise
the number of patients in the current study. According to
Simon’s two-stage minimax design, the required number of
patients was calculated to be 59 with a power of 0.80 at a
significance level of 0.05, under the assumption that a R of
0.85 would indicate potential usefulness, whereas a R of 0.7
would be the lower limit of interest.12 Assuming that 61% of
registered patients would move into the consolidation phase,
the sample size was determined to be 97 patients.
Overall survival time and progression-free survival
time were estimated by the Kaplan–Meier method, and con-
fidence intervals (CI) were based on Greenwood’s formula.13
Overall survival time was measured from the date of regis-
tration to the date of death (from any cause) or to the last
follow-up. Progression-free survival time was measured from
the date of registration to the date of disease progression,
death (from any cause), or the last follow-up. Patients who
were lost to follow-up without event were censored at the
date of their last known follow-up. A CI for RR was calcu-
lated using methods for exact binomial CIs. The Dr. SPSS II
11.0 for Windows software package (SPSS Japan Inc., To-
kyo, Japan) was used for statistical analyses.
RESULTS
Registration and Characteristics of the Patients
A total of 97 patients were enrolled in this study between
April 2001 and June 2003. Four patients were excluded from
this study before the treatment was started because the radiation
treatment planning disclosed that their tumors were too ad-
vanced for curative thoracic radiotherapy. Thus, 93 patients who
received the protocol-defined treatment were the subjects of this
analysis (Figure 2). There were 76 males and 17 females, with a
median age of 60 (range 31–74). Body weight loss was less than
5% in 77 patients; adenocarcinoma histology was noted in 57
patients, and stage IIIA disease was noted in 41 patients (Table 1).
Treatment Delivery
Treatment delivery was generally well maintained in
the chemoradiotherapy phase (Table 2). Full cycles of cispla-
tin and vinorelbine and the full dose of thoracic radiotherapy
were administered in 80 (86%) and 87 (94%) patients, re-
spectively. Delay in radiotherapy was less than 5 days in 61
(66%) patients. In contrast, the delivery of docetaxel was
poor (Table 2). A total of 59 (63%) patients could enter the
consolidation phase, and only 34 (37%) patients completed
three cycles of docetaxel chemotherapy. The reasons for not
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receiving consolidation were toxicity in 22 (65%) patients
including pneumonitis in seven patients, myelosuppression in
five patients, esophagitis in four patients, liver dysfunction in
two patients, infection in two patients, other toxicity in two
patients, progressive disease in five (15%) patients, patient
refusal in three (9%) patients, early death due to hemoptysis
in one (3%) patient, and other reasons in three (9%) patients.
Of the 59 patients, 18 (31%) discontinued docetaxel consol-
idation because of toxicity, including pneumonitis (n  14)
and esophagitis, infection, gastric ulcer, and allergic reaction
(n  1 each), four (7%) because of patient refusal, and three
(5%) because of progressive disease.
Toxicity
Acute severe toxicity in the chemoradiotherapy phase
was mainly leukopenia and neutropenia, whereas grade 3 or
4 thrombocytopenia was not noted (Table 3). Severe nonhe-
matological toxicity was sporadic, and grade 3 esophagitis
and pneumonitis were observed in only 11 (12%) and 3 (3%)
patients, respectively. Acute severe toxicity in the consolida-
tion phase also consisted of neutropenia and associated in-
fection (Table 4). In addition, grade 3 or 4 pneumonitis
developed in 4 (7%) patients. The R observed in this study
was 0.05 (3 out of 57 patients), which was much lower than
the hypothetical value. Grade 3 or 4 late toxicities were
included lung toxicity in four patients, esophageal toxicity in
two patients, renal toxicity in one patient, and a second
esophageal cancer that developed 35.4 months after the start
of the chemoradiotherapy in one patient. Treatment-related
TABLE 1. Patient Characteristics
Characteristics n %
Gender
Male 76 82
Female 17 18
Age median (range) 60 31–74
Weight loss
5% 76 81
5–9% 12 13
10% 3 3
Unknown 2 2
Histology
Adenocarcinoma 57 61
Squamous cell carcinoma 23 25
Large cell carcinoma 12 13
Others 1 1
Stage
IIIA 41 44
IIIB 52 56
TABLE 3. Acute Toxicity in Chemoradiotherapy (n  93)
Grade
Toxicity 3 4 3  4 %
Leukopenia 54 18 72 77
Neutropenia 33 29 62 67
Anemia 21 0 21 23
Infection 15 1 16 17
Esophagitis 11 0 11 12
Hyponatremia 11 0 11 12
Anorexia 9 1 10 11
Nausea 5 — 5 5
Pneumonitis 3 0 3 3
Syncope 2 0 2 2
Hyperkalemia 2 0 2 2
Ileus 0 1 1 1
Cardiac ischemia 1 0 1 1
FIGURE 2. Patient registration. CDDP, cisplatin; DTX, do-
cetaxel; TRT, thoracic radiotherapy; VNR, vinorelbine.
TABLE 2. Treatment Delivery
Variables n %
Cisplatin and vinorelbine chemotherapy
Total number of cycles
3 80 86
2 10 11
1 3 3
Number of vinorelbine skips
0 63 68
1 25 27
2–3 5 5
Thoracic radiotherapy
Total dose (Gy)
60 87 94
50–59 4 4
50 2 2
Delay (days)
5 61 66
5–9 20 22
10–16 6 6
Not evaluable (60 Gy) 6 6
Docetaxel consolidation
Number of cycles
3 34 37
2 12 13
1 13 14
0 34 34
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death was observed in four (4%) patients. Of these, three
received docetaxel, and one did not. The reason for death was
pneumonitis in all patients. We calculated a V20 (the percent
volume of the normal lung receiving 20 Gy or more) on a
dose–volume histogram in 25 patients. Of these, five patients
developed grade 3 or severer radiation pneumonitis. A me-
dian V20 for these five patients was 35% (range, 26–40%),
whereas that for the remaining 20 patients was 30% (range,
17–35%) (p  0.035 by a Mann–Whitney test).
Objective Responses, Relapse Pattern,
and Survival
All 93 patients were included in the analyses of tumor
response and survival. Complete and partial responses were
obtained in 5 (5%) and 71 patients (76%), respectively, for an
overall RR of 81.7% (95% CI, 72.7–88.0%). Stable and
progressive diseases occurred in 12 (13%) and 5 (5%) pa-
tients, respectively. With a median follow-up period of 29.7
months, 38 patients developed locoregional recurrence, 32 de-
veloped distant recurrence, 4 developed both locoregional and
distant recurrences, and 19 did not. The median progression-free
survival time was 12.8 (95% CI, 10.2–15.4) months (Figure 3).
Two patients underwent salvage surgery for a recurrent primary
tumors. Conventional chemotherapy and gefitinib monotherapy
were administered after recurrence in 20 and 25 patients, respec-
tively. The median overall survival time was 30.4 (95% CI,
24.5–36.3) months. The 1-, 2-, and 3-year survival rates were
80.7, 60.2, and 42.6%, respectively. (Figure 4).
DISCUSSION
This study showed that concurrent chemoradiotherapy
with cisplatin, vinorelbine, and standard thoracic radiotherapy
was well tolerated, with a high completion rate exceeding 80%.
The incidence of acute toxicity, including 67% (62/93) of grade
3 or 4 neutropenia, 12% (11/93) of grade 3 esophagitis, and 3%
(3/93) of grade 3 pneumonitis, were comparable with other
reports of concurrent chemoradiotherapy.3,4,10 In contrast, con-
solidation docetaxel could be administered in only 59 of 93
(63%) patients eligible to participate in this study. Of the
remaining 34 patients, 22 (65%) patients did not receive con-
solidation chemotherapy because of toxicities affecting various
organs. Other studies also showed that not all patients proceeded
to the consolidation phase after completion of concurrent che-
moradiotherapy: 61 to 78% of patients after two cycles of
cisplatin and etoposide with radiotherapy,3,10 and 54 to 75% of
patients after weekly carboplatin and paclitaxel with radiother-
apy.14,15 Thus, for 20 to 40% of the patients, concurrent chemo-
radiotherapy was as much as they could undergo, and the addi-
tional chemotherapy was not practical.
Furthermore, the number of patients who fulfilled the
three cycles of consolidation docetaxel was only 34 (58%) of
the 59 patients, which corresponded to only 37% of those
eligible in this study. The reason for the termination of
docetaxel in the 25 patients was toxicity in 18 (72%) patients,
especially pneumonitis in 14 (56%) patients. The grade of
pneumonitis during the consolidation phase was within grade
2 in most cases, and this was probably because docetaxel was
discontinued early. Considering that pneumonitis associated
with cancer treatment is more common in Japan, docetaxel
consolidation is not thought to be feasible in the Japanese
population. The MST and the 3-year survival rate in all
eligible patients were 33 months and 44% in this study, but
docetaxel consolidation was unlikely to contribute to these
promising results because only 37% of patients received full
cycles of docetaxel. This contrasts clearly with the result of
TABLE 4. Acute Toxicity in Consolidation Therapy (n  57)
Grade
Toxicity 3 4 3  4 %
Leukopenia 33 11 44 77
Neutropenia 24 26 50 88
Anemia 5 0 5 9
Infection 5 1 6 11
Esophagitis 2 0 2 3
Anorexia 1 0 1 2
Pneumonitis 2 2 4 7
FIGURE 3. Progression-free survival (n  93). The median
progression-free survival time was 12.8 (95% CI, 10.2–15.4)
months.
FIGURE 4. Overall survival (n  93). The median overall sur-
vival time was 30.4 (95% CI, 25.4–35.4) months. The 1-, 2-,
and 3-year survival rates were 80, 60, and 40%, respectively.
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the SWOG study S9504, a phase II trial of two cycles of
cisplatin and etoposide with thoracic radiation followed by
three cycles of docetaxel. In this trial, 75% of patients starting
consolidation and 59% of those entering the trial received full
cycles. In addition, docetaxel consolidation seemed to pro-
long survival, although this was drawn from a retrospective
comparison of the results between the two SWOG studies
S9504 and S9019.10
There is no widely used definition of consolidation
therapy following chemoradiotherapy. Given that consolida-
tion therapy is arbitrarily defined as chemotherapy with three
cycles or more after the completion of concurrent chemora-
diotherapy, only one randomized trial is available in the litera-
ture. The randomized phase III trial of standard chemoradio-
therapy with carboplatin and paclitaxel followed by either
weekly paclitaxel or observation in patients with stage III
NSCLC showed that only 54% of patients proceeded to
randomization, and overall survival was worse in the consol-
idation arm (MST, 16 versus 27 months).15 Thus, there have
been no data supporting the use of consolidation therapy,
especially when a third-generation cytotoxic agent such as
paclitaxel and vinorelbine is incorporated into concurrent
chemoradiation therapy.
The low complete-response rate of 5% in this study
may be explained partly by an inability to distinguish be-
tween inactive scarring or necrotic tumor and active tumor
after radiotherapy. Positron emission tomography (PET) us-
ing 18F-fluorodeoxyglucose showed a much higher rate of
complete response than conventional CT scanning and pro-
vided a better correlation of the response assessment using
PET with patterns of failure and patient survival.16 In addi-
tion, the high locoregional relapse rate in this study clearly
showed that the conventional total dose of 60 Gy was insuf-
ficient. Three-dimensional treatment planning, omission of
elective nodal irradiation, and precise evaluation of the gross
tumor volume by PET may facilitate the escalation of the
total radiation dose without enhanced toxicity.
In conclusion, cisplatin and vinorelbine chemotherapy
concurrently combined with standard thoracic radiotherapy
and followed by docetaxel consolidation produced promising
overall survival in patients with stage III NSCLC, but the vast
majority of patients could not continue with the docetaxel
consolidation because of toxicity.
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